SG11201407534PA - New diazaspirocycloalkane and azaspirocycloalkane - Google Patents

New diazaspirocycloalkane and azaspirocycloalkane

Info

Publication number
SG11201407534PA
SG11201407534PA SG11201407534PA SG11201407534PA SG11201407534PA SG 11201407534P A SG11201407534P A SG 11201407534PA SG 11201407534P A SG11201407534P A SG 11201407534PA SG 11201407534P A SG11201407534P A SG 11201407534PA SG 11201407534P A SG11201407534P A SG 11201407534PA
Authority
SG
Singapore
Prior art keywords
international
designated states
compounds
new
riehen
Prior art date
Application number
SG11201407534PA
Other languages
English (en)
Inventor
Daniel Hunziker
Patrizio Mattei
Harald Mauser
Marco Prunotto
Christoph Ullmer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201407534PA publication Critical patent/SG11201407534PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18Benzotriazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201407534PA 2012-06-13 2013-06-10 New diazaspirocycloalkane and azaspirocycloalkane SG11201407534PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12171839 2012-06-13
PCT/EP2013/061890 WO2013186159A1 (en) 2012-06-13 2013-06-10 New diazaspirocycloalkane and azaspirocycloalkane

Publications (1)

Publication Number Publication Date
SG11201407534PA true SG11201407534PA (en) 2014-12-30

Family

ID=48692428

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407534PA SG11201407534PA (en) 2012-06-13 2013-06-10 New diazaspirocycloalkane and azaspirocycloalkane

Country Status (34)

Country Link
US (3) US9493486B2 (enrdf_load_stackoverflow)
EP (1) EP2861566B1 (enrdf_load_stackoverflow)
JP (1) JP6258928B2 (enrdf_load_stackoverflow)
KR (1) KR20150023373A (enrdf_load_stackoverflow)
CN (1) CN104364239B (enrdf_load_stackoverflow)
AR (1) AR091416A1 (enrdf_load_stackoverflow)
AU (1) AU2013276617B9 (enrdf_load_stackoverflow)
BR (1) BR112014030473A2 (enrdf_load_stackoverflow)
CA (1) CA2872213A1 (enrdf_load_stackoverflow)
CL (1) CL2014003136A1 (enrdf_load_stackoverflow)
CO (1) CO7121325A2 (enrdf_load_stackoverflow)
CR (1) CR20140501A (enrdf_load_stackoverflow)
CY (1) CY1118860T1 (enrdf_load_stackoverflow)
DK (1) DK2861566T3 (enrdf_load_stackoverflow)
EA (1) EA201492223A1 (enrdf_load_stackoverflow)
ES (1) ES2618703T3 (enrdf_load_stackoverflow)
HR (1) HRP20161774T1 (enrdf_load_stackoverflow)
HU (1) HUE030526T2 (enrdf_load_stackoverflow)
IL (1) IL235826A (enrdf_load_stackoverflow)
IN (1) IN2014DN09346A (enrdf_load_stackoverflow)
LT (1) LT2861566T (enrdf_load_stackoverflow)
MA (1) MA37756B1 (enrdf_load_stackoverflow)
MX (1) MX358310B (enrdf_load_stackoverflow)
MY (1) MY180688A (enrdf_load_stackoverflow)
NZ (1) NZ702334A (enrdf_load_stackoverflow)
PE (1) PE20150230A1 (enrdf_load_stackoverflow)
PH (1) PH12014502697B1 (enrdf_load_stackoverflow)
PL (1) PL2861566T3 (enrdf_load_stackoverflow)
PT (1) PT2861566T (enrdf_load_stackoverflow)
RS (1) RS55717B1 (enrdf_load_stackoverflow)
SG (1) SG11201407534PA (enrdf_load_stackoverflow)
SI (1) SI2861566T1 (enrdf_load_stackoverflow)
TW (1) TWI633087B (enrdf_load_stackoverflow)
WO (1) WO2013186159A1 (enrdf_load_stackoverflow)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE030526T2 (en) 2012-06-13 2017-05-29 Hoffmann La Roche New diazaspirocycloalkane and azaspirocycloalkane
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
KR20150095888A (ko) 2012-12-19 2015-08-21 노파르티스 아게 오토탁신 억제제
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AR095328A1 (es) 2013-03-15 2015-10-07 Biogen Idec Inc Agentes de modulación de s1p y/o atx
WO2015048570A2 (en) * 2013-09-26 2015-04-02 Sanford-Burnham Medical Research Institute Ebi2 modulators
WO2015077503A1 (en) 2013-11-22 2015-05-28 Pharmakea, Inc. Autotaxin inhibitor compounds
KR20160087900A (ko) * 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 신규한 옥타하이드로-사이클로부타[1,2-c;3,4-c'']다이피롤-2-일
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
RS57129B1 (sr) * 2014-03-17 2018-07-31 Remynd Nv Jedinjenja 2,7-diazaspiro[3.5]nonana
SI3122750T1 (sl) 2014-03-26 2019-12-31 F. Hoffmann-La Roche Ag Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA)
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
AU2015240519B2 (en) 2014-04-04 2019-08-15 X-Rx, Inc. Substituted spirocyclic inhibitors of autotaxin
US10144732B2 (en) 2014-06-06 2018-12-04 Biogen Ma Inc. ATX modulating agents
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
CN104530046B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 二氮杂螺类化合物及其在药物中的应用
CA2974311A1 (en) 2015-01-20 2016-07-28 Novartis Ag Pet imaging agents
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN106146483A (zh) * 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
MX2017015225A (es) 2015-05-27 2018-02-19 Pharmakea Inc Inhibidores de la autotaxina y sus usos.
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
MX387736B (es) 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
PE20180552A1 (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
PE20180451A1 (es) 2015-09-24 2018-03-05 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
KR20180053408A (ko) 2015-09-24 2018-05-21 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물
MX383856B (es) 2016-06-14 2025-03-14 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2.
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
CN108456208B (zh) * 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
SG11202003825TA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Spirocyclic compounds as farnesoid x receptor modulators
ES2963652T3 (es) 2017-11-01 2024-04-01 Bristol Myers Squibb Co Compuestos espirocíclicos de alquenos como moduladores del receptor x farnesoide
ES2944657T3 (es) 2017-11-01 2023-06-23 Bristol Myers Squibb Co Compuestos de alqueno como moduladores del receptor farnesoide X
EP3704107B1 (en) 2017-11-01 2023-04-12 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid x receptor modulators
SG11202003827YA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Bridged bicyclic compounds as farnesoid x receptor modulators
UY37957A (es) * 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
MX2020004557A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
US11414418B2 (en) * 2018-01-23 2022-08-16 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2020119896A1 (en) * 2018-12-11 2020-06-18 F. Hoffmann-La Roche Ag Heterocyclic inhibitors of atx
US20210363152A1 (en) * 2018-12-11 2021-11-25 Hoffmann-La Roche Inc. Aminoazine amides
JP7465883B2 (ja) 2019-02-15 2024-04-11 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとしての置換二環式化合物
AU2020223150A1 (en) 2019-02-15 2021-10-07 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid X receptor modulators
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
JP7449300B2 (ja) 2019-02-15 2024-03-13 ブリストル-マイヤーズ スクイブ カンパニー ファルネソイドx受容体モジュレータとして有用な置換アミド化合物
JP2022116370A (ja) * 2019-06-13 2022-08-10 アグロカネショウ株式会社 新規な1-ベンジルアミン誘導体及びこれを有効成分とする農園芸用薬剤
TWI854147B (zh) * 2020-08-21 2024-09-01 南韓商治納輔醫藥科技有限公司 對前列腺素e2受體具有抑制活性的新穎化合物及其用途
KR20230128511A (ko) 2021-01-05 2023-09-05 자이두스 라이프사이언시즈 리미티드 신규한 오토택신 억제제
AU2022214618A1 (en) 2021-01-29 2023-08-17 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
CA3225439A1 (en) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1252898B (de) * 1965-06-12 1967-10-26 Bayer Ag Verfahren zur Herstellung von Copolymerisaten des Trioxans
US5240928A (en) 1989-07-03 1993-08-31 Merck & Co., Inc. Substituted quinazolinones as angiotensin II antagonists
DE3930262A1 (de) * 1989-09-11 1991-03-21 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
CA2037630C (en) 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
US5470975A (en) 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
US5290780A (en) 1991-01-30 1994-03-01 American Cyanamid Co. Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5238942A (en) 1991-05-10 1993-08-24 Merck & Co., Inc. Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists
US5202322A (en) 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
US5532243A (en) 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
US5358951A (en) 1993-04-23 1994-10-25 American Cyanamid Company Angiotensin II receptor blocking 2, 3, 6 substituted quinazolinones
DE4407047A1 (de) 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
US20010016657A1 (en) 1997-03-18 2001-08-23 Smithkline Beecham P.L.C. Substituted isoquinoline derivatives and their use as anticonvulsants
WO1999040070A1 (fr) * 1998-02-04 1999-08-12 Banyu Pharmaceutical Co., Ltd. Derives d'amine n-acyle cyclique
JP2001039950A (ja) * 1999-07-30 2001-02-13 Banyu Pharmaceut Co Ltd N−アシル環状アミン誘導体
CA2389034A1 (en) * 1999-10-27 2001-05-03 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
JP2004529113A (ja) 2001-03-07 2004-09-24 ファイザー・プロダクツ・インク ケモカイン受容体活性のモジュレーター
US7667053B2 (en) 2002-04-12 2010-02-23 Merck & Co., Inc. Bicyclic amides
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
WO2005023762A1 (en) 2003-09-04 2005-03-17 Abbott Laboratories Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
SE0302811D0 (sv) * 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
WO2005084667A1 (en) 2004-03-03 2005-09-15 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2005121145A2 (en) 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds
EP1797050B1 (en) 2004-08-10 2013-10-23 Janssen Pharmaceutica NV Hiv inhibiting 1.2.4-triazin-6-one derivates
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
CN101166736B (zh) 2005-04-28 2013-02-06 惠氏公司 他那普戈特的多晶型ⅱ
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
EP2657235A1 (en) * 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
PT1961744E (pt) * 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
US20070208001A1 (en) * 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
JP2008031064A (ja) 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体
NZ575426A (en) 2006-09-11 2010-09-30 Organon Nv Quinazolinone and isoquinolinone acetamide derivatives useful for the treatment of disorders which are influenced by modulation of the activity of the hpa axis
AR062790A1 (es) * 2006-09-15 2008-12-03 Schering Corp Derivados de azetidina utiles en el tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
US7915299B2 (en) 2006-11-15 2011-03-29 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
MX2009009920A (es) 2007-03-29 2009-10-19 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
CL2008001002A1 (es) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
KR20100015975A (ko) 2007-04-27 2010-02-12 사노피-아벤티스 2-헤테로아릴-피롤로[3,4-c]피롤 유도체 및 SCD 억제제로서의 이들의 용도
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
EP3797775A1 (en) 2007-10-19 2021-03-31 Novartis AG Compositions and methods for treatment of diabetic retinopathy
PE20091017A1 (es) 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
JP2009161449A (ja) * 2007-12-28 2009-07-23 Lion Corp Ppar活性促進剤並びに美容用飲食品、皮膚外用剤及び医薬
CA2727914A1 (en) * 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
WO2010028761A1 (de) 2008-09-09 2010-03-18 Sanofi-Aventis 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren
TW201020247A (en) 2008-11-06 2010-06-01 Gruenenthal Gmbh Substituierte disulfonamide
US8188090B2 (en) * 2008-11-17 2012-05-29 Hoffman-La Roche Inc. Naphthylacetic acids
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
AU2009321867B2 (en) 2008-12-01 2015-12-10 Merck Patent Gmbh 2,5-Diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer
TW201035102A (en) * 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
TW201038572A (en) * 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
AU2010234087B2 (en) * 2009-04-02 2016-05-12 Merck Patent Gmbh Piperidine and piperazine derivatives as autotaxin inhibitors
CN102365271B (zh) 2009-04-02 2014-05-14 默克专利有限公司 作为自分泌运动因子抑制剂的杂环化合物
EP2414346B1 (en) 2009-04-02 2015-06-24 Merck Patent GmbH Autotaxin inhibitors
FR2945534B1 (fr) 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2010135524A1 (en) * 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
US20120083476A1 (en) * 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
DE102009033392A1 (de) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclische Verbindungen als Autotaxin-Inhibitoren II
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
PL2521450T3 (pl) 2010-01-07 2015-07-31 Du Pont Grzybobójcze związki heterocykliczne
WO2011115813A1 (en) * 2010-03-18 2011-09-22 Abbott Laboratories Lactam acetamides as calcium channel blockers
ME02330B (me) * 2010-03-19 2016-06-20 Pfizer Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspir0[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora
CA2794211A1 (en) 2010-03-26 2011-09-29 Wolfgang Staehle Benzonaphthyridinamines as autotaxin inhibitors
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
EP2575794A2 (en) 2010-06-04 2013-04-10 B.S.R.C. "Alexander Fleming" Autotaxin pathway modulation and uses thereof
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
EP2606031B1 (en) 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
AU2011297961B2 (en) 2010-09-02 2015-07-02 Merck Patent Gmbh Pyrazolopyridinone derivatives as LPA receptor antagonists
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
US9260416B2 (en) 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
WO2013033059A1 (en) * 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
JPWO2013065712A1 (ja) * 2011-10-31 2015-04-02 東レ株式会社 ジアザスピロウレア誘導体及びその医薬用途
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
US9815851B2 (en) 2011-12-02 2017-11-14 Phenex Pharmaceuticals Ag Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
TWI638802B (zh) 2012-05-24 2018-10-21 芬蘭商奧利安公司 兒茶酚o-甲基轉移酶活性抑制化合物
HUE030526T2 (en) 2012-06-13 2017-05-29 Hoffmann La Roche New diazaspirocycloalkane and azaspirocycloalkane
MX359293B (es) 2012-06-13 2018-09-24 Incyte Holdings Corp Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).
WO2014018891A1 (en) 2012-07-27 2014-01-30 Biogen Idec Ma Inc. Compounds that are s1p modulating agents and/or atx modulating agents
US9522889B2 (en) 2012-07-27 2016-12-20 Biogen Ma Inc. ATX modulating agents
HK1214169A1 (zh) 2012-09-25 2016-07-22 Bayer Pharma Aktiengesellschaft 用於治疗癌症的瑞戈非尼和乙酰水杨酸的组合
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
FR2996608B1 (fr) 2012-10-05 2024-05-10 Turbomeca Couvercle de compresseur centrifuge, assemblage de couvercle et de compresseur centrifuge, et turbomachine comportant un tel assemblage
WO2014066659A1 (en) 2012-10-25 2014-05-01 Tetra Discovery Partners, Llc. Heteroaryl inhibitors of pde4
US20160002247A1 (en) 2013-03-01 2016-01-07 The University Of Tokyo 8-substituted imidazopyrimidinone derivative having autotaxin inhibitory activity
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR102224992B1 (ko) 2013-03-12 2021-03-10 애브비 인코포레이티드 테트라사이클릭 브로모도메인 억제제
US9133154B2 (en) 2013-03-12 2015-09-15 Acucela Inc. Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders
AR095328A1 (es) 2013-03-15 2015-10-07 Biogen Idec Inc Agentes de modulación de s1p y/o atx
PE20160521A1 (es) 2013-07-18 2016-05-20 Novartis Ag Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
SI3057959T1 (en) 2013-10-17 2018-07-31 Vertex Pharmaceuticals Incorporated DNA-PK INHIBITORS
WO2015077503A1 (en) 2013-11-22 2015-05-28 Pharmakea, Inc. Autotaxin inhibitor compounds
AR098475A1 (es) 2013-11-26 2016-06-01 Bayer Cropscience Ag Compuestos pesticidas y usos
KR20160087900A (ko) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 신규한 옥타하이드로-사이클로부타[1,2-c;3,4-c'']다이피롤-2-일
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
WO2015144480A1 (en) 2014-03-26 2015-10-01 Basf Se Substituted [1,2,4]triazole and imidazole compounds as fungicides
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
SI3122750T1 (sl) 2014-03-26 2019-12-31 F. Hoffmann-La Roche Ag Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA)
AU2015240519B2 (en) 2014-04-04 2019-08-15 X-Rx, Inc. Substituted spirocyclic inhibitors of autotaxin
EP3207043B3 (en) 2014-10-14 2019-10-02 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
EA033497B1 (ru) 2015-02-15 2019-10-31 Hoffmann La Roche 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN104927727B (zh) 2015-07-06 2017-01-11 香山红叶建设有限公司 一种玻璃幕墙用结构密封胶及其制备方法
PL415078A1 (pl) 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
MX387736B (es) 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
PE20180451A1 (es) 2015-09-24 2018-03-05 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
PE20180552A1 (es) 2015-09-24 2018-04-02 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de atx/ca
KR20180053408A (ko) 2015-09-24 2018-05-21 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물
KR20180054830A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 오토탁신(atx) 억제제로서의 이환형 화합물
PE20181298A1 (es) 2015-11-25 2018-08-07 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
WO2017094750A1 (ja) 2015-12-01 2017-06-08 日本農薬株式会社 3h‐ピロロピリジン化合物若しくはそのn‐オキサイド、又はそれらの塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法
WO2017139978A1 (zh) 2016-02-19 2017-08-24 吴伟东 手机app更新方法及系统
CN110392679B (zh) 2017-03-16 2023-04-07 豪夫迈·罗氏有限公司 可用作双重atx/ca抑制剂的杂环化合物
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ.ホフマン-ラ ロシュ アーゲー Atxインヒビターとしての新規二環式化合物
EP3483164B1 (en) 2017-03-20 2020-03-04 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators

Also Published As

Publication number Publication date
PH12014502697A1 (en) 2015-01-26
ES2618703T3 (es) 2017-06-22
CA2872213A1 (en) 2013-12-19
US9493486B2 (en) 2016-11-15
HK1202545A1 (en) 2015-10-02
AU2013276617A1 (en) 2014-11-20
DK2861566T3 (en) 2017-02-27
MY180688A (en) 2020-12-07
MX2014015049A (es) 2015-03-03
TW201402545A (zh) 2014-01-16
PE20150230A1 (es) 2015-02-06
EP2861566A1 (en) 2015-04-22
IN2014DN09346A (enrdf_load_stackoverflow) 2015-07-17
MA37756B1 (fr) 2018-09-28
MX358310B (es) 2018-08-14
NZ702334A (en) 2016-11-25
CR20140501A (es) 2014-12-02
WO2013186159A1 (en) 2013-12-19
JP2015519380A (ja) 2015-07-09
HRP20161774T1 (hr) 2017-02-24
CL2014003136A1 (es) 2015-02-27
HUE030526T2 (en) 2017-05-29
CO7121325A2 (es) 2014-11-20
US20170029425A1 (en) 2017-02-02
TWI633087B (zh) 2018-08-21
EP2861566B1 (en) 2016-12-21
LT2861566T (lt) 2017-02-10
PT2861566T (pt) 2017-02-08
MA37756A1 (fr) 2018-01-31
CN104364239B (zh) 2017-08-25
KR20150023373A (ko) 2015-03-05
PH12014502697B1 (en) 2015-01-26
CY1118860T1 (el) 2018-01-10
JP6258928B2 (ja) 2018-01-10
AU2013276617B9 (en) 2018-03-29
CN104364239A (zh) 2015-02-18
SI2861566T1 (sl) 2017-03-31
AR091416A1 (es) 2015-02-04
EA201492223A1 (ru) 2015-03-31
IL235826A0 (en) 2015-02-01
US20200207769A1 (en) 2020-07-02
US20150099734A1 (en) 2015-04-09
US10633384B2 (en) 2020-04-28
PL2861566T3 (pl) 2017-06-30
RS55717B1 (sr) 2017-07-31
IL235826A (en) 2017-07-31
BR112014030473A2 (pt) 2017-06-27
AU2013276617B2 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201408261UA (en) Syringe
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201403402VA (en) Compounds
SG11201408536WA (en) METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201406888QA (en) Lysin-glutamic acid dipeptide derivatives
SG11201408385TA (en) Methods of detecting diseases or conditions
SG11201407859YA (en) Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201407533SA (en) Antiviral compounds
SG11201407596TA (en) Conjugation reagents
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201406787TA (en) Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201407229UA (en) Substituted pyrazole compounds as lpar antagonists
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201407617XA (en) Endless shaped article